Data on Lung Cancer Detailed by Researchers at Midwestern University (Modest Association of Long-term Ace Inhibitor Treatment With Lung Cancer: the Promise and Pitfalls of Epidemiological Drug-safety Analyses)

摘要

2021 MAY 05 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - Investigators publish new report on Oncology - Lung Cancer. According to news reporting originating from Glendale, Arizona, by NewsRx editors, the research stated, "Results of the carefully executed Evaluation of Treatment with Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer (ERACER) study, reported in this issue, echo those of several previous observational analyses of the association of long-term angiotensin-converting enzyme (ACE) inhibitor use with incident lung cancer. These epidemiological drug-safety analyses merit cautious interpretation." Our news editors obtained a quote from the research from Midwestern University, "First, the number needed to harm (NNH) of 6667 reported in ERACER for ACE inhibitors compared with angiotensin-2 receptor blockers (ARBs) after approximately 12 years of follow-up should be balanced against therapeutic benefits.